In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.

Summary, in English

CYP3A metabolic activity varies between individuals and is therefore a possible candidate of influence on the therapeutic outcome of the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) patients. The aim of this study was to investigate the influence of CYP3A metabolic activity on the plasma concentration and outcome of imatinib in CML patients.

• Author: Karin Skoglund; Johan Richter; Ulla Olsson-Strömberg; Jonas Bergquist; Warunika Aluthgedara; S J Kumari A Ubhayasekera; Svante Vikingsson; Anna Svedberg; Stina Söderlund; Anna Sandstedt; Anders Johnsson; Jesper Aagesen; Jonas Alsenhed; Staffan Hägg; Curt Peterson; Kourosh Lotfi; Henrik Gréen
• Department/s: Division of Molecular Medicine and Gene Therapy; StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
• Publishing year: 2016
• Language: English
• Pages: 230-238
• Publication/Series: Therapeutic Drug Monitoring
• Volume: 38
• Issue: 2
• Links: http://www.ncbi.nlm.nih.gov/pubmed/26693810?dopt=Abstract; http://dx.doi.org/10.1097/FTD.0000000000000268
• Document type: Journal article
• Publisher: Lippincott Williams & Wilkins
• Topic: Hematology
• Status: Published
• ISBN/ISSN/Other: ISSN: 0163-4356